BD Pioneers New Standard in Surgical Safety with FDA-Cleared Surgiphor™ 1000mL for Wound Irrigation

Rhea-AI Summary

BD (NYSE: BDX) received FDA 510(k) clearance on March 2, 2026 for Surgiphor™ 1000mL, the first 1000 mL antimicrobial irrigation system designed for powered lavage. Surgiphor™ 1000mL is terminally sterile, ready-to-use, and built to integrate with common powered lavage devices to standardize wound irrigation and improve OR efficiency.

Key features include a powered-device adapter, Y-connector for quick switching, optimized flow with integrated venting, and a collapsible bottle for handling and evacuation.

Positive

• FDA 510(k) clearance granted for Surgiphor 1000mL on March 2, 2026
• First 1000 mL antimicrobial irrigation system designed for powered lavage
• Ready-to-use terminally sterile PVP-I solution eliminates manual mixing, saving OR time
• Includes powered-device adapter and Y-connector for quick integration and switching

Negative

• Not indicated for use as an antimicrobial at or within the wound site

News Market Reaction – BDX

+0.03%

+0.03% Session close to close

In the Mar 2 session, BDX gained 0.03%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights FDA 510(k) clearance for Surgiphor™ 1000mL, expanding BD’s antimicrobia...

Analysis

This announcement highlights FDA 510(k) clearance for Surgiphor™ 1000mL, expanding BD’s antimicrobial irrigation offerings with a ready-to-use, terminally sterile PVP‑I solution designed for powered lavage workflows. It follows earlier product and diagnostic launches and sits alongside recent balance sheet actions, including tender offers up to $2,000,000,000 of senior notes. Investors may track adoption of the new configuration, future device clearances, and any additional updates on capital structure or insider trading activity to gauge ongoing impact.

Key Figures

Irrigation volume: 1000 mL

1 metrics

Irrigation volume 1000 mL Surgiphor™ 1000mL antimicrobial irrigation system configuration

Historical Context

5 past events · Latest: Feb 25 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Feb 25	Debt tender pricing	Positive	-2.4%	Priced large debt tender offers and disclosed accepted principal allocations.
Feb 25	Tender offers upsized	Positive	-0.8%	Increased Aggregate Offer Cap to $2B and raised sub-cap on 2044 notes.
Feb 23	Conference appearance	Neutral	-1.0%	Announced upcoming presentation at Barclays Global Healthcare Conference.
Feb 23	Product launch	Positive	-0.6%	Introduced BD Vacutainer Urine Complete Cup Kit to improve testing workflows.
Feb 19	Leadership change	Neutral	+1.6%	Appointed Lanesha Minnix as executive vice president and general counsel.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent product and capital structure announcements often saw negative or muted next-day moves, with several positive or strategic updates followed by selling pressure.

Recent Company History

Over the last few weeks, BD has focused on balance sheet actions and product innovation. Debt tender offers up to $2,000,000,000 (with upsized caps) and related 8‑K filings coincided with modest share price declines. Operationally, BD announced expanded diagnostic tools and a new general counsel, which drew mixed reactions. Today’s 510(k) clearance for Surgiphor™ 1000mL continues the theme of product-line expansion following the earlier Vacutainer® urine kit launch, against a backdrop of continued insider selling and debt optimization moves.

Key Terms

510(k) clearance, powered lavage, operating room (or), terminally sterile, +1 more

5 terms

510(k) clearance regulatory

"announced it received 510(k) clearance from the U.S. Food and Drug Administration"

A 510(k) clearance is a U.S. regulatory approval that lets a medical device be sold because it is shown to be substantially similar to an already-legal device; think of it as a passport saying the new product is close enough to a known item to enter the market without a full, lengthy review. For investors, 510(k) clearance signals faster, lower-cost market access and reduced regulatory risk compared with new, untested device pathways, which can materially affect timelines, costs and revenue prospects.

powered lavage medical

"only 1000 mL antimicrobial irrigation system specifically designed for powered lavage"

Powered lavage is a mechanized surgical cleaning tool that uses a controlled stream of fluid and suction to wash away blood, debris, bacteria and loose tissue from wounds, bone or joint surfaces—think of it like a gentle pressure washer for the inside of the body. It matters to investors because these devices are sold to hospitals and can influence procedure time, infection rates, and patient outcomes, so product performance, safety data, regulatory approvals and reimbursement decisions can meaningfully affect the revenues and risk profile of companies that make them.

operating room (or) medical

"solution designed to improve patient care and operating room (OR) efficiency"

An operating room (OR) is a specially designed, sterile space in a hospital or clinic where surgeons and their teams perform operations using specialized equipment. For investors, the number, condition and usage rate of ORs signal a health care provider’s capacity to deliver paid surgical services, affect revenue potential, capital spending needs and operational risk (such as infection control or regulatory compliance), similar to how a restaurant’s kitchen determines how many meals it can cook and sell.

terminally sterile medical

"Part of the only surgical irrigation portfolio that provides terminally sterile PVP-I solutions"

A product described as "terminally sterile" has been sterilized after being sealed in its final container (for example by heat or radiation), rather than relying only on sterile handling during filling. For investors this matters because terminal sterilization reduces contamination risk, can ease regulatory review and extend shelf life, but may affect manufacturing choices and costs — like sealing and pasteurizing food to keep it safe instead of hoping it stays clean after packing.

pvp-i medical

"provides terminally sterile PVP-I solutions in multiple sizes and delivery formats."

PVP‑I (povidone‑iodine) is a topical antiseptic that pairs iodine with a carrier molecule to quickly kill bacteria, viruses and fungi on skin, mucous membranes and surfaces. For investors, it matters because it is a regulated healthcare product with steady institutional demand—like a reliable household disinfectant for hospitals—so changes in approvals, supply, procurement contracts or new clinical uses can affect sales, margins and the outlook for companies that make or supply it.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

The first and only innovation of its kind to receive 510(k) clearance, Surgiphor™ 1000mL empowers surgical teams with a consistent, antimicrobial solution designed to improve patient care and operating room (OR) efficiency

FRANKLIN LAKES, N.J., March 2, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the Surgiphor™ 1000mL. As the first and only 1000 mL antimicrobial irrigation system specifically designed for powered lavage, Surgiphor™ 1000mL provides a standardized, OR-ready solution that enhances surgical safety and efficacy.

This latest addition to the Surgiphor™ portfolio empowers clinicians to mechanically loosen and remove debris and microorganism from wounds within powered irrigation workflows. By simplifying these complex procedures, Surgiphor™ 1000mL delivers the consistency, efficiency, and ease of use across a broad range of complex surgical procedures.

Surgiphor™ 1000mL arrives ready-to-use and completely sterile, eliminating the need for hospital staff to mix solutions by hand. This saves valuable time in the operating room while helping hospitals meet global safety guidelines for surgical wound cleaning. 

"This FDA clearance reinforces BD's position as the global leader in surgical irrigation innovation," said Rian Seger, worldwide president of the BD Surgery business. "Surgiphor™ 1000mL is a unique solution that provides the consistency and safety surgical teams expect from BD, allowing them to focus on what matters most: providing better, safer care for their patients."

Building on the adoption of the original Surgiphor™ system, the Surgiphor™ 1000mL configuration gives operating room teams a larger-volume option engineered to fit seamlessly into existing powered irrigation setups.

Key features of Surgiphor™ 1000mL:

• Designed for powered irrigation: Compatible with many commonly used powered lavage devices, allowing quick integration into current OR practice.
• Versatile interchangeability: Includes a powered-device adapter, Y-connector for simple switching between saline and Surgiphor™ solution, and a twist cap for manual use when needed.
• Optimized flow and ergonomics: Integrated venting promotes smooth, unrestricted flow, while a collapsible bottle supports efficient evacuation and handling.
• Terminally sterile PVP‑I solution: Part of the only surgical irrigation portfolio that provides terminally sterile PVP-I solutions in multiple sizes and delivery formats.

The expanded Surgiphor™ portfolio now offers both manual and powered irrigation configurations, giving clinicians flexibility to match the needs of their workflow and patient population. For more information about Surgiphor™ 1000mL or the Surgiphor™ Antimicrobial Irrigation System, visit bd.com/surgiphorsystem.

*Not indicated for use as an antimicrobial at or within the wound site.

About BD
BD is one of the world's largest pure-play medical technology companies with a Purpose of advancing the world of health™ by driving innovation across medical essentials, connected care, biopharma systems and interventional. The company supports those on the frontlines of healthcare by developing transformative technologies, services and solutions that optimize clinical operations and improve care for patients. Operating across the globe, with more than 60,000 employees, BD delivers billions of products annually that have a positive impact on global healthcare. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase clinical efficiency, improve safety and expand access to healthcare. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/, X  @BDandCo or Instagram @becton_dickinson.

Contacts:
Media	Investors
Matt Marcus VP, Public Relations Matt.Marcus@bd.com	Shawn Bevec SVP, Investor Relations Investor_Relations@bd.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/bd-pioneers-new-standard-in-surgical-safety-with-fda-cleared-surgiphor-1000ml-for-wound-irrigation-302700540.html

SOURCE BD (Becton, Dickinson and Company)

FAQ

What did BD (BDX) announce about Surgiphor 1000mL on March 2, 2026?

BD announced FDA 510(k) clearance for Surgiphor 1000mL, a 1000 mL antimicrobial irrigation system designed for powered lavage. According to BD, the product is terminally sterile, ready-to-use, and engineered to integrate with common powered irrigation devices to improve OR efficiency.

Is Surgiphor 1000mL compatible with existing powered lavage devices (BDX)?

Yes, Surgiphor 1000mL is designed for powered irrigation and compatible with many commonly used devices. According to BD, it includes a powered-device adapter and Y-connector to allow quick integration into current operating room workflows.

How does Surgiphor 1000mL save time in the operating room (BDX)?

Surgiphor 1000mL arrives sterile and ready-to-use, removing the need to mix solutions by hand. According to BD, this reduces preparation time, supports global safety guidelines, and simplifies powered irrigation procedures for surgical teams.

What are the key design features of Surgiphor 1000mL from BD (BDX)?

Key features include integrated venting for smooth flow, a collapsible bottle for efficient evacuation, a powered-device adapter, and a Y-connector for switching between saline and Surgiphor solution. According to BD, these improve ergonomics and workflow compatibility.

Does Surgiphor 1000mL have limitations or usage warnings (BDX)?

Surgiphor 1000mL is explicitly not indicated for use as an antimicrobial at or within the wound site. According to BD, this labeling clarifies intended use and guides clinicians on appropriate application of the product.

How does Surgiphor 1000mL expand the Surgiphor portfolio (BDX)?

The 1000mL configuration adds a larger-volume option to Surgiphor's manual and powered irrigation lineup, offering more flexibility for different procedures. According to BD, this builds on prior adoption and supports varied clinical workflows.